Literature DB >> 6322573

Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol.

K McIntosh, S C Kurachek, L M Cairns, J C Burns, B Goodspeed.   

Abstract

An infant with severe combined immunodeficiency syndrome (SCIDS) secondary to adenosine deaminase deficiency had pneumonitis and combined infection with respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3). Four separate courses of ribavirin were delivered by small-particle aerosol. The PIV3 disappeared during the first course, and RSV disappeared after the fourth course on the 58th hospital day. Neither virus returned during profound immunosuppression for bone marrow transplantation. Secretory antibody to both viruses was found and may have assisted in recovery. Strains of RSV from the 9th, 15th, 29th, and 55th hospital days showed similar sensitivities to ribavirin in vitro. Ribavirin can be a useful drug in the treatment of respiratory viral infections in patients with SCIDS.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6322573     DOI： 10.1001/archpedi.1984.02140410083024

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN： 0002-922X


  29 in total

1.  Ribavirin in respiratory syncytial virus infection. A double blind placebo controlled trial is needed.

Authors:  D Isaacs; E R Moxon; D Harvey; I Kovar; C R Madeley; R J Richardson; M Levin; A Whitelaw; N Modi
Journal:  Arch Dis Child       Date:  1988-08       Impact factor: 3.791

2.  Detection of respiratory syncytial virus antigen in nasal washings by Abbott TestPack enzyme immunoassay.

Authors:  C G Wren; B J Bate; H B Masters; B A Lauer
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

3.  Rapid detection of respiratory syncytial virus and influenza A virus in cell cultures by immunoperoxidase staining with monoclonal antibodies.

Authors:  M Waris; T Ziegler; M Kivivirta; O Ruuskanen
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 4.  Economic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection.

Authors:  N J Snell
Journal:  Lung       Date:  1990       Impact factor: 2.584

5.  Diagnosis and treatment of viral infections.

Authors:  P L Ogra; B Volovitz
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

Review 6.  Antiviral therapy with small particle aerosols.

Authors:  V Knight; B Gilbert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

Review 7.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

8.  Time-resolved fluoroimmunoassay compared with virus isolation for rapid detection of respiratory syncytial virus in nasopharyngeal aspirates.

Authors:  M Waris; P Halonen; T Ziegler; S Nikkari; G Obert
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

9.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

10.  Rapid detection of respiratory syncytial virus in nasopharyngeal secretions by enzyme-linked immunosorbent assay.

Authors:  B A Lauer; H A Masters; C G Wren; M J Levin
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.